SANA Sana Biotechnology, Inc. Insider Trading

FMR LLC sold 290,912 shares for $1,887,319.52 at $6.49 avg; stock down 67.5% from 52-week high at $3.66

FMR LLC, a 10% owner, executed 4 separate sales totaling 290,912 shares for $1,887,319.52 on January 8, 2025, reducing holdings from 4,832,423 shares to 4,541,511 shares (a 6.0% reduction). The blended average sale price was $6.49, but the stock now trades at $3.66, representing a 43.6% decline from the transaction price. The company is unprofitable with a net loss of $-59,924,000.00 over the most recent full fiscal year. Across FMR LLC's cross-ticker insider trading history, prior sales show a 90-day well-timed rate of 100.00%, indicating the insider's prior sell decisions were followed by stock declines. This sale occurred as the stock trades severely depressed relative to its 52-week high of $11.27 and contrasts with recent momentum (+56.4% over 30 days).

Director Mulligan Richard sold 300,000 shares (10.0% of holdings) across 2 transactions at $4.08–$3.89, while SANA trades 62.1% below 52-week high amid $-50.3M annual losses.

Director Mulligan Richard executed two separate sales totaling 300,000 shares for $1,195,740.00 on consecutive trading days (2024-09-24 and 2024-09-25) at a blended average price of $3.99. The sales reduced his holdings from 2,998,121 shares to 2,698,121 shares. This activity occurs against a backdrop of significant operational losses (net income $-50,291,000.00 for the most recent full fiscal year) and sharp stock price depreciation: SANA trades at $4.27, representing a 62.1% decline from the 52-week high of $11.27 and a 26.1% drop over the prior 30 days. The combination of discretionary sales by a director during a period of negative profitability and pronounced downward price momentum deserves investor scrutiny regarding insider confidence in the company's near-term trajectory.